In addition to pushing cuts off until the beginning of 2027, the bill would update the data collection period used to establish the 2027 lab rates from 2019 to 2025.

The trial is being run by the Global Alzheimer's Platform Foundation in partnership with the UK Dementia Research Institute.

The Danaher subsidiary aims to meet clinician needs for flexibility with a range of test size options for its vast installed base.

The US Food and Drug Administration-approved comprehensive genomic profiling test will be reimbursed at a rate of $2,989.55 per test.

The firm's CEO expects lab capital expenditures to return to normal by the second half of 2026 as the overall life science ...

The company said that preliminary Q4 revenue was up 39 percent year over year and full-year 2025 revenue increased 35 percent ...

The bill was one of several discussed during a Thursday hearing by the Health Subcommittee of the House of Representatives' ...

Altai Capital said last month it had "serious concerns about the company’s significant share price underperformance." ...

President and CEO Sam Raha characterized the company's pipeline of new products as "more robust than we've had in five years." ...

The Spanish company will use the funding to accelerate the clinical transition of its LiverAce Combo assay for drug-induced liver injury assessment.

NEW YORK — Several Delta Dental dental health plan administrators said on Thursday that they will begin coverage of OraLiva's oral cancer test.

Chairman and CEO Adam Schechter said that deals may open up as hospital systems grow concerned about Medicaid cuts and the end of Affordable Care Act subsidies.